肝细胞癌相关的核编码线粒体基因及临床信息的综合预后模型
|
|
克德尔亚·艾山江, 傅怡, 赖冬林, 邬海龙, 龚伟
|
An integrated prognostic model of nuclear-encoded mitochondrial gene signature and clinical information for hepatocellular carcinoma
|
|
Aishanjiang Kedeerya, FU Yi, LAI Donglin, WU Hailong, GONG Wei
|
|
表2 不同风险组患者的基本特征
|
Tab 2 Baseline characteristics of the patients in different risk groups
|
|
| Feature | TCGA (n=339) | GEO (n=219) |
|---|
| High-risk group | Low-risk group | P value | High-risk group | Low-risk group | P value |
|---|
| Age/n(%) | | | 0.681 | | | 0.969 | | ≤50 years | 36 (21.30) | 39 (22.94) | | 53 (11.93) | 58 (52.73) | | | >50 years | 133 (78.73) | 131 (77.06) | | 56 (88.07) | 52 (47.27) | | | Gender/n(%) | | | 0.254 | | | 0.156 | | Male | 107 (63.31) | 124 (72.94) | | 96 (88.07) | 93 (84.55) | | | Female | 62 (36.69) | 46 (27.06) | | 13 (11.93) | 17 (15.45) | | | Stage/n(%) | | | 0.000 | | | 0.000 | | Ⅰ+Ⅱ | 89 (52.66) | 165 (97.06) | | 65 (59.63) | 105 (95.45) | | | Ⅲ+Ⅳ | 80 (47.34) | 5 (2.94) | | 44 (40.37) | 5 (4.55) | | | AFP/n(%) | | | 0.031 | | | 0.045 | ≤20 ng·mL-1 (TCGA) or ≤300 ng·mL-1 (GEO) | 118 (69.82) | 111 (65.29) | | 57 (52.29) | 61 (55.45) | | >20 ng·mL-1 (TCGA) or >300 ng·mL-1 (GEO) | 51 (30.18) | 59 (34.71) | | 52 (47.71) | 49 (44.55) | | | Event/n(%) | | | | | | | | Survival | 92 (54.44) | 131 (77.06) | | 57 (52.29) | 78 (70.91) | | | Death | 77 (45.56) | 39 (22.94) | | 52 (47.71) | 32 (29.09) | |
|
|
|